Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who pissed in your corn flakes? I don't know who you think you're scaring in here but your tactics are laughable.
Speaking of POS penny stock, you should stick to pumping NTEK.
A buyout is almost certain. When there's a firm dollar amount floated, MNKD will gap to or very near that price.
Shooting for a few extra basis points of profit by actively trading this is going to stop out some people eventually.
For starters it's been no secret that affreza was not going to replace long lasting insulin.
You don't get daily exposure to diabetics, especially type II diabetics in the pediatric ICU. I'm a radiologist and have done some interventional work. I see the effects of diabetes hourly.
You have no idea.
Taking insulin is not a binary function. You don't just take it and you're set, blood sugar needs dynamic and ongoing maintenance. The more strictly blood sugar is regulated, the more effectively the devastating consequences of chronic hyperglycemia can be mitigated (eg. small vessel and nerve damage, renal injury/failure, ischemic cardiomyopathy and stroke). That's a huge bundle of morbidity right there. Affreza will be easy to use and compliance is everything. Diabetes is a huge money pit and getting bigger all the time.
Headline in AMA daily executive summary:
Leading the News
FDA approves inhalable diabetes medication.
News that the FDA approved Friday an inhalable diabetes medication, Afrezza. was covered by major US newspapers, news agencies and by at least one television network. Several media outlets highlighted the challenges faced by the product’s manufacturer, MannKind Corp., and how the medication was approved in the shadow of failures of other companies to develop such a product. NBC Nightly News (6/27, story 7, 0:35, Williams) reported in its broadcast the “news will be of big interest for millions of Americans living with diabetes.”
According to the New York Times (6/28, Pollack, Subscription Publication) the approval marks a “milestone in a long and expensive journey for its developer,” MannKind. The piece also highlighted the company’s challenges, noting the firm “has not signed up a larger pharmaceutical company to help market Afrezza, even though it has said for years that it was in discussions with potential partners.”
The Wall Street Journal (6/28, Beckerman, Silverman, Subscription Publication) reported the medication has drawn the spotlight on Wall Street because of its potential to capture market share from treatments that require regular injections.
The Los Angeles Times (6/28, Pfeifer, Hennigan) highlighted that the medication is for people with Type 1 and Type 2 diabetes, noting the FDA has added a “warning that the product shouldn’t be used by those with diabetes who also have asthma or a serious lung disease.” The paper also provided details of the medication, noting “the drug is a powder that is administered through a device about the size of an asthma inhaler.” The Times pointed out that it “would be most often used to help control blood-sugar levels at mealtime, a quick puff replacing a needle injection before a meal.”
According to the AP (6/30), the FDA has cautioned that Afrezza “is not a substitute for long-acting insulin and is a new option for controlling insulin levels during meals.” According to the piece, “several other companies have failed to make inhaled insulin work commercially,” noting the example of Pfizer Inc.’s discontinued inhaled insulin Exubera in 2007 and Eli Lilly & Co.’s 2008 ending of its development program, “citing regulatory uncertainty.”
The news was also covered by Bloomberg News (6/30, Chen), the Tennessean (6/27), the San Fernando Valley (CA) Business Journal (6/27), HealthDay (6/30), MedPage Today (6/30) and Medscape (6/30).
I categorically agree. EOM
Forget what you here from squawk boxes that full decision was a done deal and already baked in to the price.
I'm in a position to gamble, so I've been sitting tight on a good chunk. That being said, I've been keeping dry powder on hand for just this event. I wish I had been paying attention on Friday afternoon to get some $8's, but oh well. There is probably enough residual fear, confusion and doubt stirred up by Friday's action and the shorts noise to shake to tree a bit more.
Human growth hormone is chemically similar to insulin and insulin-like growth factor and but one of many examples of complex compounds that require parenteral administration to avoid destruction through digestion. Pandora's box is opening.
It's worth remembering that the Affreza's delivery system has proven safety and efficacy (though pharmacokinetics and bioavailability with other active components besides an insulin analogue will require study). Big pharma with the long view is going to gobble this puppy up.
Many traders and investors were already checked out for the weekend. This was a bear raid amplified by the boxed warning regarding risk of bronchospasm in smokers, asthmatics and COPD patients.
I'm a radiologist and I see plenty of smokers, asthmatics, COPD patients and diabetics. There is limited overlap between pulmonary morbidity and diabetes. Smoking is even somewhat protective with regard to diabetes as smokers on average have less issues with obesity. Either way, a smoker diagnosed with diabetes is on a bullet train to vascular disease and these patients have dire motivation to quit smoking. Now with Inhalable insulin they have yet another reason to quit. Any one who's really worried about numbers only needs to consider that the prevalence of diabetes world wide (particularly in China and India) is exploding. Demand will outstrip supply for this drug.
Shorts must be sweating bullets this weekend. MNKD MOASS would be nice to see this coming week
There's no market competition for inhaled, ultra-rapid onset insulin. Not yet..
Thank you for bringing that to our collective attention.
Huge "duh" moment for me at least.
Matthew Marsenison must have a boat load of connections based on that info.
I think you mean FIND your women and whisky, GLGT is about to launch.
Share price settling very gently on bare bones volume. It could be months before our news comes.
I'm ok with this. Hopefully most of us feel similar.
You know you're in a stock near ground floor when some investors have yet grasp that the Shell has been sold.
"Maybe for sure" sums it up
From what I've seen Mathiassen (sp?) and Farias have had dealings with multiple segments of the private aviation industry. My guess is their new corporate entity will be in the leasing and repair fields.
Volume and money flow is a harbinger of a big week to come for GLGT. Watching the L2 I got the sense that buyers quite urgently wanted in. This has been my bottom dollar OTC play for going on 2 months and yesterday was quite an outlier day.
It seems like a telling coincidence that the contact number of Turbine Aviation MGMT was disseminated to 3 people the night before the buying spree. I haven't heard any reports back from anyone saying they've made contact with the company of late, but money talks and the market is listening.
Great day here. Good volume and consolidation in the mid-upper .005 area.
Definitely some impressive cash flow in this today.
Something's brewing.
That's something. I wonder how much of the volume today came from people who caught wind of GLGt while trolling the post post stream.
Naked shorts?
Loving the volume.
Pure speculation on my part.
Maybe someone got through to MGMT , liked what they heard and passed it along to a few friends.
This is only the beginning. EOM
Interesting stuff going on here.
Personally I'm preparing to hold out through the end of the year. That being said, I'm also prepared to look at my account at any given moment and see GLGT exploding to copperland.
Things are happening behind the PR scenes. MGMT will unveil the final complexion of the new company when requisite pieces are in place.
The timing is up to them. Unlike the usual P&D's in Pinkyland, these guys are plastering the market wire with fluffy PRs in order to unload shares.
Patience is going to pay. I don't think that getting this onto the breakout boards is necessarily a good thing. ADHD addled traders looking to yank their daily scalp will get bored after a few sessions without news.
There's enough serious investors in this too keep the pps buoyant through steady accumulation. The breakout will be effortless and epic with news.
Stronger hands. Eom
Done deal. Set to unload at .5
OTC market has two flat tires. I've closed out half of my positions over the past couple weeks. GLGT is my largest position and will it be my last until the tide turns.
Catalyst coming. Boom time
If this play can't make dollars, then this whole market doesn't make sense. IMO
GLGT is my bell weather stock. The OTC has been decimated after the SEC pot stock crack down. Once a few good plays come along to add true value the money flows might start anew.
GLGT may be blasting off very soon. Shell play, MGMT about ready for official unveiling.
No worries. The warm sentiment is appreciated nonetheless.
Float being locked means we won't need much buying pressure to blow the lid off.
So for you the price is a very good deal or a flagrantly amazing deal.